CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B
(1) Background: The lack of specific targets has slowed the progress of CAR-T in treating solid tumors. Recent studies have revealed that EDB-FN (fibronectin extra domain B) may be an effective target for CAR-T treatment of solid tumors; EDB-FN is expressed in tumor and embryonic tissues, and antibo...
Main Authors: | Zhijie Zhang, Chang Liu, Zhe Yang, Hongping Yin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/18/2863 |
Similar Items
-
Fibronectin extra domain a limits liver dysfunction and protects mice during acute inflammation
by: Vivek Krishna Pulakazhi Venu, et al.
Published: (2023-06-01) -
Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
by: Alessandro Malara, et al.
Published: (2022-09-01) -
RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer
by: Ryan C. Hall, et al.
Published: (2023-02-01) -
Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
by: Yuna Jo, et al.
Published: (2020-07-01) -
Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
by: Monique Dontenwill, et al.
Published: (2013-01-01)